NYSE:MD - MEDNAX Stock Price, Forecast & News

MEDNAX trades on the New York Stock Exchange (NYSE) under the ticker symbol "MD."

MEDNAX Inc (NYSE:MD) announced its quarterly earnings data on Friday, November, 1st. The company reported $0.91 earnings per share for the quarter, beating analysts' consensus estimates of $0.83 by $0.08. The business earned $888.70 million during the quarter, compared to the consensus estimate of $876.20 million. MEDNAX had a negative net margin of 40.86% and a positive return on equity of 10.38%. The company's revenue for the quarter was down .9% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $0.94 EPS. View MEDNAX's Earnings History.

MEDNAX is scheduled to release their next quarterly earnings announcement on Thursday, February 6th 2020. View Earnings Estimates for MEDNAX.

MEDNAX updated its fourth quarter earnings guidance on Friday, November, 1st. The company provided earnings per share (EPS) guidance of $0.87-0.95 for the period, compared to the Thomson Reuters consensus EPS estimate of $0.93.

11 brokers have issued 12 month target prices for MEDNAX's stock. Their forecasts range from $18.00 to $34.00. On average, they expect MEDNAX's stock price to reach $27.73 in the next year. This suggests a possible upside of 0.1% from the stock's current price. View Analyst Price Targets for MEDNAX.

11 Wall Street analysts have issued "buy," "hold," and "sell" ratings for MEDNAX in the last year. There are currently 2 sell ratings, 7 hold ratings and 2 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for MEDNAX.

Media stories about MD stock have trended extremely negative recently, according to InfoTrie. InfoTrie identifies negative and positive press coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. MEDNAX earned a media sentiment score of -5.0 on InfoTrie's scale. They also assigned news articles about the company a news buzz of 10.0 out of 10, meaning that recent press coverage is extremely likely to have an effect on the stock's share price in the near term. View News Stories for MEDNAX.

MEDNAX saw a decline in short interest during the month of December. As of December 31st, there was short interest totalling 6,370,000 shares, a decline of 6.2% from the December 15th total of 6,790,000 shares. Based on an average trading volume of 1,180,000 shares, the short-interest ratio is presently 5.4 days. Currently, 7.9% of the company's stock are short sold. View MEDNAX's Current Options Chain.

Some companies that are related to MEDNAX include Laboratory Corp. of America (LH), Quest Diagnostics (DGX), Davita (DVA), Chemed (CHE), Amedisys (AMED), LHC Group (LHCG), AMN Healthcare Services (AMN), BioScrip (BIOS), CorVel (CRVL), R1 RCM (RCM), Tivity Health (TVTY), The Providence Service (PRSC), Cross Country Healthcare (CCRN) and Interpace Diagnostics Group (IDXG).

Based on aggregate information from My MarketBeat watchlists, some companies that other MEDNAX investors own include Chevron (CVX), Dominion Energy (D), Walt Disney (DIS), Gilead Sciences (GILD), Intel (INTC), AbbVie (ABBV), CVS Health (CVS), General Electric (GE), UnitedHealth Group (UNH) and Exxon Mobil (XOM).

MEDNAX's stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include Triad Investment Management (0.07%), Sage Capital Advisors llc (0.07%), Nisa Investment Advisors LLC (0.06%), Wedge Capital Management L L P NC (0.02%), State of Alaska Department of Revenue (0.02%) and Altfest L J & Co. Inc. (0.01%). Company insiders that own MEDNAX stock include David A Clark, Dominic J Andreano, John C Pepia, Joseph M Calabro, Md Pascal J Goldschmidt, Michael Fernandez and Vivian Lopez-Blanco. View Institutional Ownership Trends for MEDNAX.

MD stock was sold by a variety of institutional investors in the last quarter, including Triad Investment Management and State of Alaska Department of Revenue. Company insiders that have sold MEDNAX company stock in the last year include David A Clark, Dominic J Andreano, John C Pepia, Joseph M Calabro and Md Pascal J Goldschmidt. View Insider Buying and Selling for MEDNAX.

MD stock was bought by a variety of institutional investors in the last quarter, including Nisa Investment Advisors LLC, FNY Investment Advisers LLC, Wedge Capital Management L L P NC, Sage Capital Advisors llc and Altfest L J & Co. Inc.. View Insider Buying and Selling for MEDNAX.

Shares of MD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of MD stock can currently be purchased for approximately $27.69.

MEDNAX has a market capitalization of $2.33 billion and generates $3.65 billion in revenue each year. The company earns $268.62 million in net income (profit) each year or $3.51 on an earnings per share basis. MEDNAX employs 7,625 workers across the globe.View Additional Information About MEDNAX.

The official website for MEDNAX is http://www.mednax.com/.

MEDNAX's mailing address is 1301 CONCORD TERRACE, SUNRISE FL, 33323. The company can be reached via phone at 954-384-0175 or via email at [email protected]